113 related articles for article (PubMed ID: 7995044)
1. In vivo/in vitro correlation of xenografts in nude mice and the ATP-cell viability assay.
Perras JP; Hurst J
Contrib Gynecol Obstet; 1994; 19():122-31. PubMed ID: 7995044
[No Abstract] [Full Text] [Related]
2. Application of the ATP-cell viability assay for assessment of in vitro radiation treatment response in gynecologic cancer cell lines.
Rodriguez M; Steren AJ
Contrib Gynecol Obstet; 1994; 19():156-65. PubMed ID: 7995047
[No Abstract] [Full Text] [Related]
3. Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay.
Untch M; Sevin BU
Contrib Gynecol Obstet; 1994; 19():145-55. PubMed ID: 7995046
[No Abstract] [Full Text] [Related]
4. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
Wang X; Yuan S; Wang J; Lin P; Liu G; Lu Y; Zhang J; Wang W; Wei Y
Toxicol Appl Pharmacol; 2006 Sep; 215(2):168-78. PubMed ID: 16563451
[TBL] [Abstract][Full Text] [Related]
5. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
8. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
9. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples.
Ng TY; Ngan HY; Cheng DK; Wong LC
Gynecol Oncol; 2000 Mar; 76(3):405-8. PubMed ID: 10684718
[TBL] [Abstract][Full Text] [Related]
10. Review of data on gynecologic cancer cell lines: potential applications of ATP-cell viability assays.
Nguyen HN; Sevin BU; Perras JP; Averette HE
Contrib Gynecol Obstet; 1994; 19():132-44. PubMed ID: 7995045
[No Abstract] [Full Text] [Related]
11. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
13. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
14. [New approaches in experimental cancerology: in search of therapeutic models].
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
[No Abstract] [Full Text] [Related]
15. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo.
Cook JL; Miura TA; Iklé DN; Lewis AM; Routes JM
Cancer Res; 2003 Jun; 63(12):3435-43. PubMed ID: 12810682
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
18. [Development of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness].
Kobayashi H; Tanisaka K; Kondo N; Mito Y; Koezuka M; Yokouchi H; Higashiyama M; Kodama K; Doi O; Yamada M
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1933-9. PubMed ID: 7487123
[TBL] [Abstract][Full Text] [Related]
19. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
20. [Basic study on in vitro chemosensitivity tests].
Iijima N; Sekiya S; Tokita H; Takamizawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Feb; 43(2):191-6. PubMed ID: 2013708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]